Jiangsu Province Centers

Company snapshot

Jiangsu Province Centers is a pharma organization headquartered in CN. Primary therapeutic focus areas include H. Pylori Infection, COVID-19. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1), phase 1 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Jiangsu Province Centers. Not investment advice.

• What is Jiangsu Province Centers?

  Jiangsu Province Centers is a pharma organization headquartered in CN. Primary therapeutic focus areas include H. Pylori Infection, COVID-19. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.

• Is Jiangsu Province Centers publicly traded?

  Jiangsu Province Centers appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Jiangsu Province Centers develop or market?

  We link 5 drug profile(s) where Jiangsu Province Centers is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/jiangsu-province-centers-for-disease-control-and-prevention#company-drugs.

• What are the latest developments for Jiangsu Province Centers?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Jiangsu Province Centers focus on?

  Jiangsu Province Centers focuses on H. Pylori Infection, COVID-19 based on our analysis of their pipeline programs and drug development activities.